Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.5703
-0.0550 (-8.80%)
At close: May 6, 2026, 4:00 PM EDT
0.5540
-0.0163 (-2.86%)
Pre-market: May 7, 2026, 4:01 AM EDT
Scinai Immunotherapeutics Revenue
In the year 2025, Scinai Immunotherapeutics had annual revenue of $1.31M with 99.24% growth. Scinai Immunotherapeutics had revenue of $269.00K in the quarter ending December 31, 2025, with 30.58% growth.
Revenue (ttm)
$1.31M
Revenue Growth
+99.24%
P/S Ratio
1.51
Revenue / Employee
$42,290
Employees
31
Market Cap
1.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31M | 653.00K | 99.24% |
| Dec 31, 2024 | 658.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNI News
- 12 days ago - Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Benzinga
- 12 days ago - Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - PRNewsWire
- 4 weeks ago - Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - PRNewsWire
- 5 weeks ago - Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - PRNewsWire
- 6 weeks ago - Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - PRNewsWire
- 7 weeks ago - Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - PRNewsWire
- 2 months ago - Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - PRNewsWire
- 2 months ago - Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - PRNewsWire